title: TNF-inhibitor induced lupus in a patient treated with adalimumab for rheumatoid arthritis.
abstract: Anti-tumor necrosis factor induced lupus (ATIL) is a rare side effect reported in patients treated with anti-tumor necrosis factor medications such as infliximab, etanercept and adalimumab. Of the three, this condition has been least commonly reported secondary to adalimumab. In this report, we present a case of ATIL in a patient treated for rheumatoid arthritis (RA) with adalimumab. This report will increase physician awareness of the warning signs, diagnostic options and potential complications of ATIL. In this patient, adalimumab was discontinued and treatment was started, leading to improvement in the patient's status.
authors.affiliation: SUNY Downstate Medical Center.
authors.forename: Miriam R
authors.initials: MR
authors.lastname: Lieberman
authors.forename: Tracey N
authors.initials: TN
authors.lastname: Liebman
authors.forename: Usha
authors.initials: U
authors.lastname: Alapati
authors.forename: Amor
authors.initials: A
authors.lastname: Khachemoune
mesh_terms: D000068879:Adalimumab / Q000009:adverse effects* / Q000627:therapeutic use; D000368:Aged; D018501:Antirheumatic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D002990:Clobetasol / Q000627:therapeutic use; D003937:Diagnosis, Differential; D004359:Drug Therapy, Combination; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D008178:Lupus Erythematosus, Cutaneous / Q000139:chemically induced* / Q000188:drug therapy / Q000473:pathology; D008297:Male; D011241:Prednisone / Q000627:therapeutic use; D014221:Triamcinolone / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D018501:Antirheumatic Agents; D005938:Glucocorticoids; D014409:Tumor Necrosis Factor-alpha; D014221:Triamcinolone; D002990:Clobetasol; D000068879:Adalimumab; D011241:Prednisone